- Conditions
- Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
- Interventions
- Ranibizumab, Saline
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–80
of 80
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
- Interventions
- Intravitreal Aflibercept Injection
- Drug
- Lead sponsor
- Ophthalmic Consultants of Boston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vitreous Hemorrhage
- Interventions
- Intravitreal Aflibercept Injection, Standard Vitrectomy
- Drug · Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Faricimab
- Drug
- Lead sponsor
- Greater Houston Retina Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Bakersfield, California • Modesto, California • Orlando, Florida + 13 more
- Conditions
- Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Interventions
- dexamethasone intravitreal implant, intravitreal bevacizumab
- Drug
- Lead sponsor
- Retina Macula Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
- Interventions
- PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
- Device · Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Propranolol
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
- Drug · Other
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Hagerstown, Maryland